CA-INNODISK
21.8.2019 10:02:08 CEST | Business Wire | Press release
Innodisk, the world’s leading industrial storage provider, unveiled the InnoAGE™ SSD, the world’s first with native Microsoft Azure Sphere™ integration. Formally introduced at the Innodisk-hosted AIoT Summit during Flash Memory Summit 2019 (FMS 2019), the InnoAGE SSD, with Microsoft Azure Sphere inside, enables multifunctional management for smart data analysis and updates, data security, and remote control through the cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005192/en/
“Our tight-knit collaboration with Microsoft has resulted in real innovation aimed at solving the very real challenges businesses face today,” said Innodisk President Randy Chien. “The InnoAGE™ SSD is the first and only hybrid solution designed solely with the AIoT architecture in mind, utilizing data analysis, data security, and data management through Azure Sphere, to secure communications between all IoT and AIoT devices. This is a great milestone for both companies.”
Microsoft Azure Sphere provides the Innodisk InnoAGE SSD with an extra layer of security and remote monitoring with zero administrators required. Embedded on the edge device, the InnoAGE SSD will collect data and give commands for multifunction management through the cloud, such as error correction, updates, data analysis, AES encryption. With these capabilities, InnoAGE SSD with Microsoft Azure Sphere inside, is ideally suited for applications spanning various segments standardizing on AIoT, including manufacturing, surveillance, unmanned devices, vending machines and digital signage, among others.
The InnoAGE SSD ensures an easy-to-use interface with a customized cloud management platform. Innodisk designed firmware receives commands from Microsoft Azure Sphere which in turn connects to businesses’ Microsoft Azure Cloud deployments. Additionally, the InnoAGE SSD can execute debugging messages and help monitor read/write behavior patterns that optimize storage lifespan. Most importantly, it can quickly revert to default settings from a cloud-based dashboard if the system crashes. Lastly, the InnoAGE SSD is designed for both in-band and out-of-band network management, overcoming current recovery challenges where in-band management falls short by providing full recovery even when the operating system is down or damaged.
InnoAGE SSD is using Toshiba original WT BiCS3 64 layers and P/E 3000 times for industrial application, and it will release in two form factors: 2.5” SSD supports to 1TB, and M.2 2280 supports to 512GB, all available for wide temperature.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005192/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom